Evidence map›Paper›PMID 33287876›Full record

ArticleJournal of hematology & oncology2020

Proteomic signatures of 16 major types of human cancer reveal universal and cancer-type-specific proteins for the identification of potential therapeutic targets.

Yangying Zhou, T Mamie Lih, Jianbo Pan, Naseruddin Höti, Mingming Dong, Liwei Cao, Yingwei Hu, Kyung-Cho Cho, Shao-Yung Chen, Rodrigo Vargas Eguez and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology & oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
7.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 77 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Yangying ZhouDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA.ORCID 0000-0002-2181-0841
T Mamie LihDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA.
Jianbo PanDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA.
Naseruddin HötiDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA.
Mingming DongDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA.
Liwei CaoDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA.
Yingwei HuDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA.
Kyung-Cho ChoDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA.
Shao-Yung ChenDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA.
Rodrigo Vargas EguezDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA.
Edward GabrielsonDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA.
Daniel W ChanDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA.
Hui ZhangDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA. huizhang@jhu.edu.
Qing Kay LiDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA. qli23@jhmi.edu.
Johns Hopkins University · US

Funding

Glycoprotein biomarkers for the early detection of aggressive prostate cancerU01CA152813 · NCI · JOHNS HOPKINS UNIVERSITY · PI ZHANG, HUI · 2010 to 2021
$6.2M
The Comprehensive Proteome Characterization Center at Johns Hopkins: High Precision Discovery and Confirmation of Genoproteomic TargetsU24CA210985 · NCI · JOHNS HOPKINS UNIVERSITY · PI CHAN, DANIEL WANYUI, ZHANG, HUI · 2016 to 2020
$5.3M
NCI NIH HHS U01 CA152813NCI NIH HHS U24 CA210985NIH HHS U01CA152813NIH HHS U24CA210985
6 · The paper itself

Abstract

backgroundProteomic characterization of cancers is essential for a comprehensive understanding of key molecular aberrations. However, proteomic profiling of a large cohort of cancer tissues is often limited by the conventional approaches.

methodsWe present a proteomic landscape of 16 major types of human cancer, based on the analysis of 126 treatment-naïve primary tumor tissues, 94 tumor-matched normal adjacent tissues, and 12 normal tissues, using mass spectrometry-based data-independent acquisition approach.

resultsIn our study, a total of 8527 proteins were mapped to brain, head and neck, breast, lung (both small cell and non-small cell lung cancers), esophagus, stomach, pancreas, liver, colon, kidney, bladder, prostate, uterus and ovary cancers, including 2458 tissue-enriched proteins. Our DIA-based proteomic approach has characterized major human cancers and identified universally expressed proteins as well as tissue-type-specific and cancer-type-specific proteins. In addition, 1139 therapeutic targetable proteins and 21 cancer/testis (CT) antigens were observed.

conclusionsOur discoveries not only advance our understanding of human cancers, but also have implications for the design of future large-scale cancer proteomic studies to assist the development of diagnostic and/or therapeutic targets in multiple cancers.

Indexed as

Drug DiscoveryHumansMolecular Targeted TherapyNeoplasmsProteinsProteomeProteomicsProteinsProteomeCancer-associated proteinsCancer therapeutic targetsData-independent acquisitionProteomic analysisTissue-enriched proteins

Identifiers

PMID33287876
PMCPMC7720039
OpenAlexW3111185940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.